Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
- Sponsor
- Institute of Dermatology, Thailand
- Study ID
- NCT06202560
- Status
- Completed
Conditions
- Frontal Fibrosing Alopecia
- Lichen Planopilaris of Scalp
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Tofacitinib 5 MG — DRUGParticipants in the research will receive oral Tofacitinib medication with a dosage of 5 mg, twice a day, for 12 weeks. They will be scheduled to come for follow-up every 4 weeks throughout the 12-week period, and will continue to be followed up for 4 weeks after stopping the medication. The total duration of the research will be 16 weeks. The purpose is to evaluate the effectiveness and safety of the medication.
Study Details
This study aims to determine the efficacy and safety of tofacitinib therapy in Thai patients with recalcitrant frontal fibrosing alopecia. The main questions are 1. Does Tofacitinib significantly reduce Frontal Fibrosing Alopecia Severity Index (FFASI), Frontal Fibrosing Alopecia Severity Score (FFASS), Lichen Planopillaris Activity Index (LPPAI) compared to baseline and after 16 weeks? 2. Is Tofacitinib significantly different for adverse events compared to baseline and after 16 weeks? Participants will have a check-up in clinical and investigation and then get prescribed oral Tofacitinib 5 mg twice a day for 12 weeks. After that, they will have follow-up every 4 weeks until week 16.
Key Dates
- Start date
- Nov 29, 2023
- Status verified
- May 2025
- Primary completion
- Jul 10, 2024
- Completion
- Jul 10, 2024
Study Design
- Enrollment
- 11 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Tofacitinibtaking oral Tofacitinib 5 mg twice a day for 12 weeks
Primary Outcome Measure
Effectiveness of Oral Tofacitinib in Recalcitrant Frontal Fibrosing Alopecia(FFA) [ Time Frame: 16 weeks after taking oral Tofacitinib ]
Related coverage on Hipa.ai
- Tofacitinib Pilot Study for Frontal Fibrosing Alopecia Posts ResultsTofacitinib · May 30, 2025 · ClinicalTrials.gov
Related Studies
- Facial Papules in Frontal Fibrosing Alopecia (FFA)Not Yet Recruiting · University of Miami · Miami, Florida
- Deucravacitinib in the Treatment of Cicatricial AlopeciasPHASE2 · Recruiting · Icahn School of Medicine at Mount Sinai · New York, New York